Skip to main content
$32.07 $0.17 (0.5%)

04:00 PM EST on 03/01/24

SurModics, Inc. (NASDAQ:SRDX)

CAPS Rating: No stars

Develops, manufactures and markets innovative surface modification and drug delivery technologies for the healthcare industry.

Current Price $32.07 Mkt Cap $456.5M
Open $31.84 P/E Ratio 82.63
Prev. Close $32.07 Div. (Yield) $0.00 (0.0%)
Daily Range $31.28 - $32.45 Volume 28,739
52-Wk Range $16.00 - $39.41 Avg. Daily Vol. 58,143


How do you think NASDAQ:SRDX will perform against the market?

Add Stock to CAPS Watchlist

All Players

72 Outperform
19 Underperform

All-Star Players

7 Outperform
2 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:SRDX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

rklapman (85.06)
Submitted December 16, 2008

Expect takeover by JNJ

TMFCop (63.82)
Submitted April 14, 2009

Drug delivery unit derives most of its profits from JNJ stent business. The pharma just reported earnings that saw the stent business generate revenues that were down 28% in the U.S., 16% worldwide. On top of that appeals court says JNJ's stent… More

Recent Community Commentary

Read the most recent pitches from players about SRDX.


Member Avatar Bigsef77 (53.26) Submitted: 1/31/2019 10:21:56 AM : Outperform Start Price: $72.95 NASDAQ:SRDX Score: -132.39

Here's Why You Should Invest in Surmodics (SRDX) Stock Now
Zacks Equity Research
,Zacks•January 11, 2019

Surmodics, Inc. SRDX is expected to gain from strong growth in theIn Vitro Diagnostics (IVD)segment. Further, the company’s consistent efforts to boost research and development (R&D) functionalities buoy optimism.

Price Performance

In a year’s time, shares of this Zacks Rank #2 (Buy) company have surged 75.2%, against the industry’s 4.5% decline and the S&P 500 index’s fall of 6.6%.

Let us take a quick look at the factors that make Surmodics a solid pick for now.

IVD Segment Driving Growth

Surmodics’ performance continues to be driven by the IVD unit. For more than 35 years, the segment has been a leader in developing an ELISA/EIA, immunoblot/western blot, line assay or microarray.

In the fourth quarter of fiscal 2018, sales in the IVD increased 13.4% to $6.1 million. Per management, the segment saw strong growth in antigen and DNA slide sales in the quarter.

However, operating income in the segment was $2.4 million in the reported quarter, marginally down from the year-ago quarter’s tally. Notably, IVD revenues in the fourth quarter reflected strong growth in antigen and DNA slide sales.

Consistent Efforts to Boost R&D

Surmodics’ efforts to improve R&D stature are a key growth driver. The company’s whole product solutions pipeline and sirolimus-based below-the-knee DCB program deserve a mention here.

Fiscal fourth-quarter R&D expenses were $9.8 million, up 23.4% year over year. Considering the company’s strength in the R&D prospects, it has long-term goals of generating double-digit top line growth by the end of 2019 and EBITDA margins at or above 30% by fiscal 2021.

Which Way Are Estimates Treading?

For the first quarter of fiscal 2019, the Zacks Consensus Estimate is pegged at a loss of a penny, reflecting year-over-year decline of 101%. The same for revenues isat $18.9 million, marking 11.1% improvement year over year.

For fiscal 2019, the Zacks Consensus Estimate for earnings is pinned at 8 cents. For revenues, estimates are pegged at $93.3 million, indicating 14.8% rise year over year.

Surmodics, Inc. Price and Consensus


Member Avatar TrevorCarson (< 20) Submitted: 6/6/2018 8:55:21 AM : Outperform Start Price: $52.85 NASDAQ:SRDX Score: -125.71

discovered through sectors search (balancing risk spread)


Member Avatar chris293 (33.27) Submitted: 8/17/2014 4:50:12 PM : Outperform Start Price: $23.59 NASDAQ:SRDX Score: -109.66

This stock is trending up.


Find the members with the highest scoring picks in SRDX.

Score Leader


OOji (29.76) Score: +504.89

The Score Leader is the player with the highest score across all their picks in SRDX.

Member Name Member
Call Time
Score Commentary
OOji 29.76 3/13/2009 Underperform 1Y $17.52 +81.74% +586.63% +504.89 0 Comment
SanDieguito 62.95 1/29/2009 Underperform 3Y $20.19 +57.70% +505.43% +447.73 0 Comment
harrytong 54.65 10/17/2008 Underperform 5Y $25.60 +24.38% +471.99% +447.61 1 Comment
Nivaos 68.75 8/24/2009 Underperform 1Y $22.48 +41.64% +398.41% +356.77 0 Comment
LongStrangle 26.53 8/1/2008 Underperform NS $42.45 -24.99% +316.31% +341.30 0 Comment
motivr 65.22 1/16/2008 Underperform NS $52.75 -39.64% +286.04% +325.68 0 Comment
Justin5342002 77.83 8/11/2008 Underperform NS $39.28 -18.94% +304.50% +323.44 0 Comment
SeaShoreShells < 20 1/4/2008 Underperform 3M $52.90 -39.81% +276.77% +316.58 0 Comment
TradeSignal01 < 20 9/12/2007 Underperform NS $46.61 -31.69% +265.54% +297.23 0 Comment
fllwthldr 34.48 7/24/2007 Underperform 5Y $48.14 -33.86% +252.57% +286.43 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SRDX.